Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether à-go-go-1 potassium channels.

Astemizole inhibits cell proliferation in human prostate tumorigenic cells expressing ether à-go-go-1 potassium channels. Cell Mol Biol (Noisy-le-grand). 2017 Dec 17;63(12):11-13 Authors: Bernal-Ramos G, Hernández-Gallegos E, Vera E, Chávez-López MG, Zúñiga-García V, Sánchez-Pérez Y, Garrido E, Camacho J Abstract Prostate cancer (PC) is the main cause of cancer mortality in men worldwide. Therefore, novel treatments for PC are needed. Ether à-go-go-1 (Eag1) potassium channels display oncogenic properties, and have been suggested as early tumor markers and therapeutic targets for different cancers. These channels are overexpressed in many human tumors including PC. Astemizole targets several molecules involved in cancer including Eag1 channels, histamine receptors and ABC transporters. Here we studied Eag1 mRNA expression and protein levels in the non-tumorigenic and non-invasive human prostate RWPE-1 cell line, and in the tumorigenic and highly invasive human prostate WPE1-NB26 cell lines. The effect of astemizole on cell proliferation and apoptosis was also studied. The human prostate cell lines RWPE-1 and WPE1-NB26 were cultured following the provider´s instructions. Eag1 mRNA expression and protein levels were studied by real time RT-PCR and immunocytochemistry, respectively. Cell proliferation and apoptosis were studied by a fluorescence AlamarBlue®  assay and flow cy...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Related Links:

BOSTON (CBS) – Alex Fitzpatrick went from Hollywood screenwriter to Massachusetts restaurant owner so she and her husband could spend more time with her children. When she recently found out her risk of getting breast cancer was as high as 80%, all she could think of was her three boys. “I do want to make sure that I’m the one telling them what to wear on their wedding day and watch them go to college,” she said. Alex has one of the BRCA gene mutations. She got tested when an aunt was recently diagnosed with an aggressive form of breast cancer. “I was blindsided to be honest,” she remem...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated Local Watch Listen Angelina Jolie Breast Cancer Dr. Mallika Marshall Mass General Hospital Source Type: news
Condition:   Prostate Cancer Interventions:   Drug: Curcumin;   Drug: Placebo Sponsor:   University of Texas Southwestern Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Intervention:   Sponsors:   University of California, Irvine;   University of California, Los Angeles;   Cedars-Sinai Medical Center;   VA Medical Center-West Los Angeles;   VA Long Beach Healthcare System Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(Natural News) Prostate cancer is the second most common cancer among American men, and statistics indicate that there are over two million prostate cancer survivors currently living in the United States. It is most common in men over the age of 65 and is rated as the second most common cause of cancer-related death in...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
ConclusionsBioequivalence was demonstrated between the two abiraterone acetate products. The study also confirmed high intra-subject variability, for abiraterone: coefficient of variation (CV, %) ofCmax values for the test and reference products were 40.33% and 46.58%, while for AUC0t were 24.02% and 34.16%, respectively.Trial registrationhttp://www.chinadrugtrials.org.cn/: CTR20170997.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsThis is the first nationwide study in Spain to report long-term outcomes of patients with intermediate-risk PCa treated with EBRT. Survival outcomes were good, with a low incidence of both acute and late toxicity. Patients with unfavourable risk characteristics had significantly lower 5- and 10-year disease-free survival rates. ADT and radiotherapy dose  ≥ 74 Gy were both significant predictors of treatment outcomes.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
We present a 71-year-old Japanese man with metastasis prostate cancer that, during medical castration therapy, had torsades de pointes (TdP) with a QT prolongation and ventricular fibrillation (VF). His QT interval diminished after discontinuing the medical castration, and he developed no further VF recurrences for 15 months. Medical castration is a rare but possible trigger of TdP with QT prolongation and VF. PMID: 30518719 [PubMed - as supplied by publisher]
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Conclusion: The increases in the incidence of different types of cancer in the past decade could be due to the revolutionary change in socioeconomic status that has occurred in Saudi Arabia; therefore, a national plan should be established for cancer prevention, screening and therapy. Concerning mortality, the decrease in its percentage among elderly people could be due to biological factors that should be investigated in the future. PMID: 30520511 [PubMed - in process]
Source: Saudi Medical Journal - Category: Middle East Health Tags: Saudi Med J Source Type: research
Publication date: Available online 8 December 2018Source: European UrologyAuthor(s): Tommy Nyberg, Koveela Govindasami, Goska Leslie, Tokhir Dadaev, Elizabeth Bancroft, Holly Ni Raghallaigh, Mark N. Brook, Nafisa Hussain, Diana Keating, Andrew Lee, Romayne McMahon, Angela Morgan, Andrea Mullen, Andrea Osborne, Reshma Rageevakumar, The UK Genetic Prostate Cancer Study Collaborators, Zsofia Kote-Jarai, Rosalind Eeles, Antonis C. AntoniouAbstractBackgroundThe homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutati...
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionsThe Y-chromosomal lncRNA TTTY15 was upregulated in most PCa tissues and could promote PCa progression by sponging let-7.Patient summaryWe found that TTTY15 levels were frequently elevated in prostate cancer (PCa) tissues compared with those in paracancerous normal tissues in a large group of PCa patients, and we observed a tumour suppressive effect after TTTY15 knockout using CRISPR/Cas9. These results may have therapeutic implications for PCa patients.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Molecular Biology | Nanotechnology | Potassium | Prostate Cancer